Funding Opportunity Announcement (FOA) Number: RFA-MH-22-170 and RFA-MH-22-171 This FOA invites applications for Research Project Grants that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV. Research should focus on understanding key drivers for HIV vaccine communication success, communication strategies for engagement of communities placed at greatest risk for acquiring HIV, and/or mitigating the impact and reach of HIV vaccine misinformation. Research applications may leverage HIV vaccine analogs (e.g., COVID-19, HPV, HBV vaccines), so long as they have a primary focus on populations placed at risk for HIV, and/or healthcare settings and providers involved in HIV prevention delivery. This FOA uses the R01 grant mechanism, while RFA-MH-22-171 uses the R21 mechanism. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials should consider using the R01 mechanism. Applicants proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models or applications should consider the R21 mechanism. Posted Date: January 03, 2022
Open Date (Earliest Submission Date): April 10, 2022
Letter of Intent Due Date(s): 30 days prior to the application due date | 
No comments:
Post a Comment